Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy

British Journal of Cancer

Volumn 109, Issue 11, 2013, Pages 2765-2773

  Spencer, S K M ^a   Pommier, A J C ^a   Morgan, S R ^a   Barry, S T ^a   Robertson, J D ^a   Hoff, P M ^b,c   Jurgensmeier J M ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Biomarker; Cediranib; Colorectal cancer; FOLFOX XELOX; Prognostic predictive marker

Indexed keywords

ANGIOPOIETIN RECEPTOR; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CEDIRANIB; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BLOOD PROTEINS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 84888863037     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.649     Document Type: Article

References (14)

1. Chen E, Jonker D, Gauthier I, Maclean M, Wells J, Powers J, Seymour L (2009) Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 15: 1481-1486.
2. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054. (Pubitemid 47218051)
3. Friedman JH (2001) Greedy function approximation; a gradient boosting machine. Ann Stat 29: 1189-1232. (Pubitemid 33405972)
4. Goldberg RM (2004) Current approaches to first-line treatment of advanced colorectal cancer. Clin Colorectal Cancer 4: S9-S15. (Pubitemid 38854684)
5. Hegde PS, Jubb AM, Chen D, Li NF, Meng G, Bernaards C, Elliott R, Scherer S, Chen DS (2013) Predictive impact of circulating vascular endothelial growth factor in 4 Phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937.
6. Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP. on behalf of the HORIZON II study group (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30: 3596-3603.
7. Jürgensmeier JM, Schmoll H-J, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 108: 1316-1323.
8. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28: 453-459.
9. Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2: 234-242.
10. Ridgeway G (2007) Generalized Boosted Models: a guide to the gbm package. Available at http://cran.r-project.org/web/packages/gbm/vignettes/gbm.pdf.
11. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
12. Schmoll H-J, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. on behalf of the HORIZON III study group (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30: 3588-3595.
13. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13: 827-837.
14. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400. (Pubitemid 40775678)